Sutro Biopharma (STRO) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Voting matters and shareholder proposals
Election of three Class II directors: Jane Chung, Connie Matsui, and James Panek, with board recommending a vote for all nominees.
Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026, recommended for approval.
Advisory vote to approve compensation of named executive officers, with board recommending approval.
Board of directors and corporate governance
Board is seeking shareholder approval for the election of three Class II directors at the 2026 annual meeting.
Executive compensation and say-on-pay
Advisory vote on executive compensation is included, allowing shareholders to express approval or disapproval of named executive officer pay.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Sutro Biopharma
- Advancing next-gen ADCs with strong clinical progress and a robust, well-funded pipeline.STRO
Corporate presentation - Q2 2026 revenue was $9.8M, net loss $38.5M, and strong pipeline and cash position highlighted.STRO
Q2 2026 - Directors elected, auditor ratified, and executive pay approved; clinical goals accelerated.STRO
AGM 2026 - Accelerated ADC pipeline and strong funding drive rapid clinical progress and upcoming data readout.STRO
Jefferies Global Healthcare Conference 2026 - STRO-004 shows promise for broader solid tumor treatment with improved safety and efficacy.STRO
7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - Next-gen ADC platform delivers potent, differentiated therapies for major solid tumor indications.STRO
Corporate presentation - Net loss narrowed to $38.5M on $14.5M revenue, with $202.6M cash and runway into Q2 2028.STRO
Q1 2026 - Virtual meeting to elect directors, ratify auditor, and approve executive pay, with focus on governance.STRO
Proxy filing - Next-gen ADCs advance with robust pipeline, dual-payload innovation, and strong clinical progress.STRO
Corporate presentation